Conolidine’s analgesic effects stem from its conversation with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors from the central anxious process, conolidine modulates alternate molecular targets. A Science Improvements review found that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://johnnyn169zio2.worldblogged.com/profile